Tarsus Demonstrates Lotilaner’s Potential In Preventing Lyme Disease

Lotilaner, the active ingredient in Tarsus’s Demodex blepharitis drug Xdemvy, showed significant ability to kill ticks in a small Phase IIa study. Analysts call the Lyme program a likely out-licensing opportunity for Tarsus.

Tick warning
Tarsus may have a non-vaccine approach to preventing Lyme disease • Source: Shutterstock

More from Clinical Trials

More from Antiparasitic